Belite Bio, INC (BLTE) SEC Filings — 2025

Filings

• Belite Bio, INC 6-K Filing — 6-K · Dec 2, 2025
• Belite Bio's Tinlarebant Shows Promise in Stargardt Disease Trial — 6-K · Dec 1, 2025
• Belite Bio, INC 6-K Filing — 6-K · Nov 10, 2025
• Belite Bio Secures PIPE Financing — 6-K · Sep 8, 2025
• Belite Bio Reports Q2 2025 Financials and Corporate Update — 6-K · Aug 11, 2025
• Belite Bio Announces Registered Direct Offering — 6-K · Aug 7, 2025
• Belite Bio Completes Enrollment in Geographic Atrophy Trial — 6-K · Jul 2, 2025
• Belite Bio's Tinlarebant Gets FDA Breakthrough Therapy Designation — 6-K · May 21, 2025
• Belite Bio Reports Q1 2025 Results and Corporate Update — 6-K · May 14, 2025
• Belite Bio Shareholders Approve All Proposed Resolutions — 6-K · Apr 15, 2025
• Belite Bio Changes Auditors to Deloitte & Touche — 6-K · Mar 28, 2025
• Belite Bio Announces 2025 Annual Shareholder Meeting Materials — 6-K · Mar 18, 2025
• Belite Bio Reports Q4 & FY 2024 Results — 6-K · Mar 17, 2025
• Belite Bio Files 2024 Annual Report — 20-F · Mar 17, 2025
• Belite Bio Releases Interim Phase 3 Stargardt Trial Data — 6-K · Feb 27, 2025
• Belite Bio Prices $1M Direct Offering of ADSs and Warrants — 6-K · Feb 6, 2025